Fresenius moves forward with two U.S. expansions after killing Akorn deal

URLhttps://www.fiercepharma.com/manufacturing/freseni
SourceFierce Pharma
Date Published04/10/2019
Author NameEric Palmer
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Fresenius Kabi
Parent company Fresenius
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):445
Year reshoring announced:2017
Year reshoring implemented or to be implemented:2022
Capital investment ($):100
Country(ies) from which reshored:Germany
City reshored to:Wilson
State(s) reshored to:NC
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredpharmaceuticals
What domestic positive factors made reshoring more attractive?Eco-system synergies, Government Incentives, Proximity to customers/market
Find Reshoring Articles